08 August 2018
Visiongain’ has launched a new pharma report Global Smoking Cessation Drugs Market Forecast 2017-2027: NRT, Non-nicotine Pharmacotherapy, Prescription Drugs, OTC Drugs
This report is intended to provide an in-depth analysis of the latest trends prevailing in the Global Smoking Cessation Drugs Market and its growth and development in the next decade. The changing demographics of the world population, developing infrastructure, emerging economies, consumer spending behaviour, per capita income, macroeconomic factors, rising GDPs, and the reformation in laws and regulations are trend setting factors, which will affect the market. Nicotine replacement therapy and pharmacotherapy are approved to aid in smoking cessation. While nicotine replacement products can be available as prescription drugs or over-the-counter medicines, pharmacotherapeutic treatments are available only by prescription
The lead analyst of the report commented “The Global Smoking Cessation Drugs market is influenced by several factors during the forecast period. The market is influenced by decreasing prevalence of tobacco smoking, increasing awareness about diseases and comorbidities fuelled by tobacco smoking, increasing regulation of vaping products market, availability of multiple dosage forms of NRT products, as well as various national and international level policies being adopted by a growing number of countries to combat tobacco smoking”
Leading companies featured in the report include Pfizer, Johnson & Johnson (J&J), GlaxoSmithKline (GSK), 22nd Century Group, Inc, Chrono Therapeutics, Cerecor Inc, Selecta Biosciences, Embera NeuroTherapeutics, CV Sciences
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The 431-page report provides clear detailed insight into the generic drugs market. Discover the key drivers and challenges affecting the market.
03 July 2020
Where is the Clinical Workflow Solutions market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2030, assessing data, trends, opportunities and business prospects there.
03 July 2020
With the growing burden of rare diseases around the world, there has been a rise and advancement in the therapy development of these types of diseases. While the fact remains that over 90% of these diseases lack approval for treatment and the total number of terminal rare diseases to receive the first treatment every year remains low.
01 July 2020
The market growth is attributed to the growing adoption of big data and AI in data management and monitoring of clinical information in health care.